QDEL - Quidel Corporation
| Previous Close | 58.79 |
| Open | 59.02 |
| Bid | 57.05 x 800 |
| Ask | 57.12 x 800 |
| Day's Range | 56.80 - 59.02 |
| 52 Week Range | 44.27 - 77.63 |
| Volume | 78,528 |
| Avg. Volume | 182,487 |
| Market Cap | 2.27B |
| Beta (3Y Monthly) | 1.70 |
| PE Ratio (TTM) | 35.54 |
| EPS (TTM) | 1.60 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.40 |
- Business Wire•7 days ago
Quidel Receives 510(k) Clearance for Quidel Triage® TOX Drug Screen, 94600 Toxicology Test for Use With Quidel’s Triage® MeterPro Instrumented System
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received 510(k) clearance from the Unites States Food and Drug Administration (FDA) to market the Quidel Triage® TOX Drug Screen, 94600, a fluorescence immunoassay for the qualitative determination of the presence of drug and/or metabolites in human urine of up to 9 drug assays. The test is to be used with Quidel’s Triage® MeterPro instrumented system.
- Zacks•13 days ago
Medical Products Industry Outlook: Growth Prospects Radiant
Medical Products Industry Outlook: Growth Prospects Radiant
- Zacks•14 days ago
QDEL vs. BAX: Which Stock Is the Better Value Option?
QDEL vs. BAX: Which Stock Is the Better Value Option?
- Zacks•14 days ago
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
- Insider Monkey•15 days ago
Is Quidel Corporation (QDEL) A Good Stock To Buy?
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
- Zacks•15 days ago
Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech
Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech
- Zacks•15 days ago
Ecolab Unveils Innovative Tested Tool to Improve Food Safety
Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.
- Zacks•15 days ago
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- Zacks•16 days ago
Here's Why You Should Retain HMS Holdings (HMSY) Stock
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.
- Zacks•16 days ago
4 Top Efficient Stocks to Boost Your Portfolio
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
- Simply Wall St.•17 days ago
Should You Be Adding Quidel (NASDAQ:QDEL) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Zacks•19 days ago
Here's Why You Should Retain NextGen Healthcare (NXGN) Stock
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
- Investor's Business Daily•20 days ago
Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar
Medical technology stocks hit record highs last year and are rising thus far in 2019. Two of the fastest growing among them have tacked on double-digit earnings growth for several years.
- Zacks•20 days ago
Here's Why You Should Invest in DexCom (DXCM) Stock Now
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
- Business Wire•22 days ago
Quidel Announces Private Exchange Transactions
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.25% Convertible Senior Notes due 2020 (the “2020 Notes”). Pursuant to these exchange agreements Quidel will exchange approximately $45.372 million in aggregate principal amount of the 2020 Notes for (i) approximately 1,273,601 shares of the company’s common stock plus (ii) an additional number of newly issued shares of the company’s common stock to be determined based on the volume weighted average price of the company’s common stock over the three consecutive trading days commencing on June 5, 2019.
- Zacks•23 days ago
Here's Why You Should Hold on to Medidata (MDSO) Stock Now
Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.
- Zacks•29 days ago
Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.
- Zacks•last month
Here's Why You Should Consider Betting On CONMED Stock Now
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.
- Simply Wall St.•last month
Here's What Quidel Corporation's (NASDAQ:QDEL) P/E Ratio Is Telling Us
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
- Zacks•last month
ABIOMED Gets FDA Confirmation of the Safety of Impella RP
ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.
- Business Wire•last month
Quidel to Present at William Blair 39th Annual Growth Stock Conference
Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 39th Annual Growth Stock Conference at the Loews Chicago hotel in Chicago, Illinois on Thursday, June 6, 2019. Randy Steward, chief financial officer, will present on Thursday, June 6, 2019 at 1:20 p.m. Central Time (11:20 a.m. Pacific Time) with a question-and-answer session scheduled immediately following the presentation. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.
- Zacks•last month
Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring
Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.
- Zacks•last month
Here's Why You Should Retain Cooper Companies (COO) Stock
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.
- Thomson Reuters StreetEvents•last month
Edited Transcript of QDEL earnings conference call or presentation 8-May-19 9:00pm GMT
Q1 2019 Quidel Corp Earnings Call
- Zacks•last month
Here's Why You Should Retain DaVita (DVA) in Your Portfolio
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.
